Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Unreported exclusion and sampling bias in interpretation of randomized controlled trials in patients with STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John Wong
  • Logan B Smith
  • Eli A Magun
  • Thomas Engstrom
  • Kirsten Kelley-Howard
  • Dakshina M Jandhyala
  • Cheleste M Thorpe
  • Bruce E Magun
  • Lisa J Wood
View graph of relations
The adverse side effects of doxorubicin, including cardiotoxicity and cancer treatment-related fatigue, have been associated with inflammatory cytokines, many of which are regulated by mitogen-activated protein kinases (MAPKs). ZAK is an upstream kinase of the MAPK cascade. Using mouse primary macrophages cultured from ZAK-deficient mice, we demonstrated that ZAK is required for the activation of JNK and p38 MAPK by doxorubicin. Nilotinib, ponatinib and sorafenib strongly suppressed doxorubicin-mediated phosphorylation of JNK and p38 MAPK. In addition, these small molecule kinase inhibitors blocked the expression of IL-1β, IL-6 and CXCL1 RNA and the production of these proteins. Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1β RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone. Therefore, by reducing the production of inflammatory mediators, the inhibitors identified in the current study may be useful in minimizing the side effects of doxorubicin and potentially other chemotherapeutic drugs.
Original languageEnglish
JournalCancer Biology & Therapy
Volume14
Issue number1
Pages (from-to)56-63
Number of pages8
ISSN1538-4047
DOIs
Publication statusPublished - Jan 2013

    Research areas

  • Animals, Antibiotics, Antineoplastic, Cells, Cultured, Chemokine CXCL1, Doxorubicin, Gene Expression, Inflammation, Inflammation Mediators, Interleukin-1beta, Interleukin-6, Liver, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Macrophages, Mice, Mice, Inbred C57BL, Mice, Knockout, Protein Kinase Inhibitors, Pyrimidines

ID: 42942791